☆ 4.7 Editorial Material

Fezolinetant for menopausal hot flashes and night sweats

TRENDS IN PHARMACOLOGICAL SCIENCES (2023)

Efficacy and Safety of Fezolinetant in Moderate to Severe Vasomotor Symptoms Associated With Menopause: A Phase 3 RCT

Kimball A. Johnson et al.

Summary: This study assessed the efficacy and safety of fezolinetant for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause. The results showed that fezolinetant 30 mg and 45 mg reduced VMS frequency and severity significantly compared to placebo, and were well tolerated.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2023)

添加到收藏夹

Article Medicine, General & Internal

Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study

Samuel Lederman et al.

Summary: This study investigated the safety and efficacy of fezolinetant, a non-hormonal therapy, for the treatment of vasomotor symptoms in menopausal women. The results showed that fezolinetant significantly reduced the frequency and severity of vasomotor symptoms compared to placebo, and the improvements were maintained over 52 weeks.

LANCET (2023)

添加到收藏夹

Article Pharmacology & Pharmacy

Fezolinetant in the treatment of vasomotor symptoms associated with menopause

Herman Depypere et al.

Summary: Although international clinical practice guidelines recognize the continued role of menopausal hormone therapy (HT), concerns over safety and tolerability have led to the search for non-hormonal alternatives such as fezolinetant, a neurokinin-3 receptor (NK3R) antagonist. Fezolinetant has shown promising results in reducing VMS frequency and severity, presenting a potential non-hormonal option for menopausal symptom relief.

EXPERT OPINION ON INVESTIGATIONAL DRUGS (2021)

添加到收藏夹

Article Obstetrics & Gynecology